Accelerating Biomedical Research with an AI-Powered Database of Disease Genes, Mutations, and Animal Models.

Smartly Shaping the Future of Antibodies, Empowering New Drug Discovery

AlphaKnockout Gene Targeting Expert System

Learn how Cyagen’s huHSC-NKG-ProF model enhances immune reconstitution to support more predictive immunotherapy studies. Led by immunology expert Dr. Joyce Yu, this session explores model applications in ADCC, tumor vaccines, and immune-targeted combination therapies—along with CRO strategies for translational success.

From hMAPT to 6-OHDA rats, Cyagen offers validated models for Alzheimer’s, Parkinson’s, SMA, and depression. Leverage our full-service CRO platform for model development, phenotyping, and drug efficacy testing.

A new RPGR-deficient mouse model mimics human XLRP. Targeted Gene Editing-Pro delivered via AAV significantly preserved photoreceptors and restored protein expression, offering long-term therapeutic potential for RPGR-related vision loss.

From BD-368-2 antibodies to mRNA-1273 vaccines, breakthroughs in COVID-19 research depend on reliable mouse models. Learn how neutralizing antibodies are screened and how ACE2-modified mice are used to evaluate safety and immunogenicity.

The humanized B6-hSNCA mouse model by Cyagen faithfully expresses the human SNCA gene, providing a robust platform for Parkinson’s and DLB research. This model helps in evaluating small nucleic acids, gene editing therapies, and novel PD treatments.

Cyagen’s MeCP2 knockout (KO) mouse models replicate critical RTT symptoms, enabling mechanistic research and therapeutic testing. These mice are pivotal in advancing treatments, including gene therapy and symptom-targeting drugs for RTT.

Cyagen’s achromatopsia mouse models are instrumental in advancing gene therapy treatments. By mimicking genetic mutations in CNGA3, CNGB3, and GNAT2, these models offer a critical platform for developing AAV-mediated gene therapy for this debilitating disorder, paving the way for clinical breakthroughs.